LGALS13: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
imported>Boghog
Consistent citation formatting
 
Line 1: Line 1:
{{Infobox_gene}}
{{Infobox_gene}}
'''Galactoside-binding soluble lectin 13''' or '''placental protein 13''' (PP13) is a [[protein]] that in humans is encoded by the ''LGALS13'' [[gene]].<ref name="pmid6856484">{{cite journal |vauthors=Bohn H, Kraus W, Winckler W | title = Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17) | journal = Oncodev Biol Med | volume = 4 | issue = 5 | pages = 343–50 |date=Jul 1983 | pmid = 6856484 | pmc =  | doi =  }}</ref><ref name="pmid10527825">{{cite journal |vauthors=Than NG, Sumegi B, Than GN, Berente Z, Bohn H | title = Isolation and sequence analysis of a cDNA encoding human placental tissue protein 13 (PP13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden Crystal protein | journal = Placenta | volume = 20 | issue = 8 | pages = 703–10 |date=Dec 1999 | pmid = 10527825 | pmc =  | doi = 10.1053/plac.1999.0436 }}</ref><ref name="entrez">{{cite web | title = Entrez Gene: LGALS13 lectin, galactoside-binding, soluble, 13 (galectin 13)| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=29124| accessdate = }}</ref>
'''Placental protein 13''' (PP13) is a [[protein]] that in humans is encoded by the ''LGALS13'' [[gene]].<ref name="pmid6856484">{{cite journal | vauthors = Bohn H, Kraus W, Winckler W | title = Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17) | journal = Oncodevelopmental Biology and Medicine | volume = 4 | issue = 5 | pages = 343–50 | date = Jul 1983 | pmid = 6856484 | pmc =  | doi =  }}</ref><ref name="pmid10527825">{{cite journal | vauthors = Than NG, Sumegi B, Than GN, Berente Z, Bohn H | title = Isolation and sequence analysis of a cDNA encoding human placental tissue protein 13 (PP13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden Crystal protein | journal = Placenta | volume = 20 | issue = 8 | pages = 703–10 | date = November 1999 | pmid = 10527825 | pmc =  | doi = 10.1053/plac.1999.0436 }}</ref>


==Structure and function==
==Structure and function==
<!-- The PBB_Summary template is automatically maintained by Protein Box Bot.  See Template:PBB_Controls to Stop updates. -->
== Function ==
{{PBB_Summary
 
| section_title =
It is composed of two identical subunits which are held together by disulfide bonds. The monomer of this protein has structural similarity to several members of the beta-galactoside-binding S-type lectin family, but it could not bind beta-galactoside. This is because the ligand binding site is lack of key residue for binding beta-galactoside. <ref name="pmid29343868">{{cite journal | vauthors = Su J, Wang Y, Si Y, Gao J, Song C, Cui L, Wu R, Tai G, Zhou Y | title = Galectin-13, a different prototype galectin, does not bind β-galacto-sides and forms dimers via intermolecular disulfide bridges between Cys-136 and Cys-138 | journal = Scientific Reports | volume = 8 | issue = 1 | pages = 980 | date = January 2018 | pmid = 29343868 | doi = 10.1038/s41598-018-19465-0 }}</ref>It is a galectin-like protein. The ligand of this protein is still unknown.
| summary_text = Lysophospholipases are enzymes that act on biological membranes to regulate the multifunctional lysophospholipids. The protein encoded by this gene has lysophospholipase activity. It is composed of two identical subunits which are held together by disulfide bonds. This protein has structural similarity to several members of the beta-galactoside-binding S-type lectin family.<ref name="entrez" />
}}


==Clinical significance==
==Clinical significance==
PP13 levels that are low in the first trimester of pregnancy confers a higher risk for developing [[pre-eclampsia]] later in pregnancy.<ref name="pmid23420029">{{cite journal |vauthors=Huppertz B, Meiri H, Gizurarson S, Osol G, Sammar M | title = Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia | journal = Hum. Reprod. Update | volume = 19| issue = 4| pages = 391–405|date=February 2013 | pmid = 23420029 | doi = 10.1093/humupd/dmt003 }}</ref>
PP13 levels that are low in the first trimester of pregnancy confers a higher risk for developing [[pre-eclampsia]] later in pregnancy.<ref name="pmid23420029">{{cite journal | vauthors = Huppertz B, Meiri H, Gizurarson S, Osol G, Sammar M | title = Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia | journal = Human Reproduction Update | volume = 19 | issue = 4 | pages = 391–405 | date = February 2013 | pmid = 23420029 | doi = 10.1093/humupd/dmt003 }}</ref>


==References==
== References ==
{{reflist}}
{{reflist}}
==Further reading==
{{refbegin | 2}}
{{PBB_Further_reading
| citations =
*{{cite journal  |vauthors=Wang A, Dennis EA |title=Mammalian lysophospholipases |journal=Biochim. Biophys. Acta |volume=1439 |issue= 1 |pages= 1–16 |year= 1999 |pmid= 10395961 |doi= 10.1016/s1388-1981(99)00063-3 }}
*{{cite journal  |vauthors=Uhlmann J, Wiemann S, Ponstingl H |title=DelGEF, an RCC1-related protein encoded by a gene on chromosome 11p14 critical for two forms of hereditary deafness |journal=FEBS Lett. |volume=460 |issue= 1 |pages= 153–60 |year= 1999 |pmid= 10571079 |doi=10.1016/S0014-5793(99)01333-2  }}
*{{cite journal  |vauthors=Visegrády B, Than NG, Kilár F |title=Homology modelling and molecular dynamics studies of human placental tissue protein 13 (galectin-13) |journal=Protein Eng. |volume=14 |issue= 11 |pages= 875–80 |year= 2002 |pmid= 11742106 |doi=10.1093/protein/14.11.875  }}
*{{cite journal  |vauthors=Sjölinder M, Uhlmann J, Ponstingl H |title=DelGEF, a homologue of the Ran guanine nucleotide exchange factor RanGEF, binds to the exocyst component Sec5 and modulates secretion |journal=FEBS Lett. |volume=532 |issue= 1–2 |pages= 211–5 |year= 2003 |pmid= 12459492 |doi=10.1016/S0014-5793(02)03677-3  }}
*{{cite journal  |vauthors=Strausberg RL, Feingold EA, Grouse LH |title=Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue= 26 |pages= 16899–903 |year= 2003 |pmid= 12477932 |doi= 10.1073/pnas.242603899  | pmc=139241 }}
*{{cite journal  |vauthors=Than NG, Pick E, Bellyei S |title=Functional analyses of placental protein 13/galectin-13 |journal=Eur. J. Biochem. |volume=271 |issue= 6 |pages= 1065–78 |year= 2004 |pmid= 15009185 |doi=10.1111/j.1432-1033.2004.04004.x  }}
*{{cite journal  |vauthors=Burger O, Pick E, Zwickel J |title=Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies |journal=Placenta |volume=25 |issue= 7 |pages= 608–22 |year= 2004 |pmid= 15193867 |doi= 10.1016/j.placenta.2003.12.009 }}
*{{cite journal  |vauthors=Gerhard DS, Wagner L, Feingold EA |title=The Status, Quality, and Expansion of the NIH Full-Length cDNA Project: The Mammalian Gene Collection (MGC) |journal=Genome Res. |volume=14 |issue= 10B |pages= 2121–7 |year= 2004 |pmid= 15489334 |doi= 10.1101/gr.2596504  | pmc=528928 }}
*{{cite journal  |vauthors=Chafetz I, Kuhnreich I, Sammar M |title=First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction |journal=Am. J. Obstet. Gynecol. |volume=197 |issue= 1 |pages= 35.e1–7 |year= 2007 |pmid= 17618748 |doi= 10.1016/j.ajog.2007.02.025 }}
}}
{{refend}}
<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{PBB_Controls
| update_page = yes
| require_manual_inspection = no
| update_protein_box = yes
| update_summary = yes
| update_citations = yes
}}
{{gene-19-stub}}

Latest revision as of 20:39, 10 September 2018

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez

n/a

n/a

Ensembl

n/a

n/a

UniProt

n/a

n/a

RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Placental protein 13 (PP13) is a protein that in humans is encoded by the LGALS13 gene.[1][2]

Structure and function

Function

It is composed of two identical subunits which are held together by disulfide bonds. The monomer of this protein has structural similarity to several members of the beta-galactoside-binding S-type lectin family, but it could not bind beta-galactoside. This is because the ligand binding site is lack of key residue for binding beta-galactoside. [3]It is a galectin-like protein. The ligand of this protein is still unknown.

Clinical significance

PP13 levels that are low in the first trimester of pregnancy confers a higher risk for developing pre-eclampsia later in pregnancy.[4]

References

  1. ↑ Bohn H, Kraus W, Winckler W (Jul 1983). "Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17)". Oncodevelopmental Biology and Medicine. 4 (5): 343–50. PMID 6856484.
  2. ↑ Than NG, Sumegi B, Than GN, Berente Z, Bohn H (November 1999). "Isolation and sequence analysis of a cDNA encoding human placental tissue protein 13 (PP13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden Crystal protein". Placenta. 20 (8): 703–10. doi:10.1053/plac.1999.0436. PMID 10527825.
  3. ↑ Su J, Wang Y, Si Y, Gao J, Song C, Cui L, Wu R, Tai G, Zhou Y (January 2018). "Galectin-13, a different prototype galectin, does not bind β-galacto-sides and forms dimers via intermolecular disulfide bridges between Cys-136 and Cys-138". Scientific Reports. 8 (1): 980. doi:10.1038/s41598-018-19465-0. PMID 29343868.
  4. ↑ Huppertz B, Meiri H, Gizurarson S, Osol G, Sammar M (February 2013). "Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia". Human Reproduction Update. 19 (4): 391–405. doi:10.1093/humupd/dmt003. PMID 23420029.
Retrieved from "https://www.wikidoc.org/index.php?title=LGALS13&oldid=1529876"